Allogene Therapeutics, Inc.
ALLO
$1.78
-$0.09-4.57%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -42.68M | -42.61M | -38.81M | -41.40M | -50.94M |
| Total Depreciation and Amortization | 2.65M | 2.87M | 3.06M | 3.10M | 3.11M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.57M | 8.45M | 8.36M | 8.76M | 11.04M |
| Change in Net Operating Assets | 469.00K | 18.37M | -202.00K | -145.00K | -2.24M |
| Cash from Operations | -32.00M | -12.91M | -27.60M | -29.69M | -39.03M |
| Capital Expenditure | -150.00K | -9.00K | 0.00 | -243.00K | -44.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -147.41M | -29.58M | 33.61M | 12.18M | 43.88M |
| Cash from Investing | -147.56M | -29.59M | 33.61M | 11.94M | 43.84M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 187.87M | 21.12M | 7.86M | 3.24M | 1.51M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | 0.00 | 3.56M |
| Cash from Financing | 187.87M | 21.12M | 7.86M | 3.24M | 5.07M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.32M | -21.38M | 13.87M | -14.52M | 9.88M |